Hansa Biopharma AB (publ) (HNSA)
Free
No email, no account, no signup.
Pulling latest news for Hansa Biopharma AB (publ)…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Signal
NEUTRAL
Sentiment
6/10
Risk
8/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Order analysis – $4.99
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Hansa Biopharma is a biotech company developing and commercializing immunomodulating enzyme therapies. Its lead product **Idefirix (imlifidase)** enables desensitization ahead of kidney transplantation in highly sensitized patients, alongside a pipeline in autoimmune and transplant-related indica...
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Biotechnology (immunology and transplantation medicine)
Market Cap
$346M
Market sentiment
Sentiment is **neutral to slightly positive**: strong regulatory/clinical progress for imlifidase is balanced by the long wait to PDUFA, cash-burn concerns, and pipeline setbacks.
Why NEUTRAL ?
- A **binary FDA outcome** is the main valuation driver.
- Funding looks improved, but the company remains **loss-making** with high burn.
- Reasonable to **wait** for confirmation of EU sales momentum and continued FDA progress before sizing up materially.
- Hold/wait; consider scaling in cautiously (e.g., 5–10% of biotech allocation) after the Q1 report on weakness.
Recent News
- Q1 2026 (Apr 23) reported revenue of SEK 34.6m (sharply down YoY) and a large ongoing loss; management cited a short-term EU sales drag from a commercial reorganization but expects improvement from Q2. The FDA set a Dec 19, 2026 PDUFA target date for the imlifidase BLA (U.S.). Financing was strengthened via a new USD 30m convertible note (Athyrium), and cash was SEK 676.5m as of Mar 31, 2026. The share price dropped sharply around the update with unusually high trading volume.
Bull case
- The **Q1 report** could confirm continued European sales growth.
- Improved funding position reduces near-term financing pressure.
Unlock to read more →
Bear case
- High **cash burn** may weigh on the stock between catalysts.
Unlock to read more →
Catalysts
25 Jun 2026 — Capital Markets Day (New York)
Dilution Risk
Assessment: Medium
Order analysis – $4.99
Save hours of research. $4.99.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Hansa Biopharma AB (publ) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.